New blood vessel formation is necessary for the repair of ischemia-damaged tissues. Endothelial cells produce exogenous and endogenous angiogenic factors in the mediation of angiogenesis and neovasculogenesis during neovascularization. Exposure to environmental pollutants may alter proangiogenic capacity or desensitize the responses of endothelial cells to stimulation by basic fibroblast growth factor and vascular endothelial growth factor. Human umbilical vein endothelial cells (HUVECs) were pretreated with benzo[a]pyrene (B[a]P), the major carcinogenic constituent found in tobacco smoke, for 24 h. Neovasculogenesis, migration, and proliferation were evaluated in solvent-treated and B[a]P-treated HUVECs. Endothelial capillary-like tube formation, cell migration, mitogen-activated protein kinase (MAPK) phosphorylation, and integrin expression were reduced in B[a]Ptreated HUVECs with angiogenic factor stimulation, in comparison to solvent-treated HUVECs, although cell proliferation and Akt activation remained unaffected. Inhibition of B[a]P-mediated MAPK and neovasculogenesis was significantly rescued by pretreatment with a-naphthoflavone, an aryl hydrocarbon receptor (AhR) antagonist. The B[a]P-mediated inhibition of neovasculogenesis was also rescued in AhR-silenced HUVECs, suggesting the requirement for AhR in B[a]P-associated effects. B[a]P also inhibited angiogenesis in a chorioallantoic membrane assay. We conclude that B[a]P is a potent inhibitor of angiogenesis, and its effects are mediated via AhR-dependent phenotypic changes in B[a]P-treated HUVECs. These findings contribute to an understanding of the involvement of AhR agonists in vasculotoxicity.
Neovascularization is essential for tissue and organ regeneration following pathological damage in various diseases, or alternatively, for tumor development (Kajbafzadeh et al., 2007) . Angiogenesis, the formation of new capillaries from preexisting vessels, or neovasculogenesis, the in situ assembly of capillaries from angioblast precursors, both are major processes building the construction of new blood vessels and are characterized by strict endothelial regulation (Asahara et al., 1999) . Angiogenic growth factors such as basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) stimulate angiogenesis; vascular endothelial cells leave their quiescent phase and produce matrix metalloproteases, which digest the basement membranes of surrounding vessels, followed by endothelial cell proliferation, migration, and eventual differentiation to form endothelial capillary-like structure (Gerwins et al., 2000; Munoz-Chapuli and Quesada, 2004; Somanath et al., 2009) . Neovasculogenesis requires the recruitment of stem cells/endothelial progenitor cells, which differentiate into mature endothelial cells (Carmeliet, 2000) . Neovascularization potential has been proposed as a therapeutic tool to facilitate the revascularization and healing of ischemic tissues (Miranville et al., 2004; Nakagami et al., 2005; Planat-Benard et al., 2004) .
Polycyclic aromatic hydrocarbons (PAHs) are common in the environment. PAHs can be administered via the ingestion of contaminated food and water or by inhalation of tobacco smoke and the exhausts from factories and motor vehicles (Mastrangelo et al., 1996; Philips, 1999) . Benzo [a] pyrene (B[a]P), a major carcinogenic PAH in tobacco smoke, is an agonist for the aryl hydrocarbon receptor (AhR). AhR ligands induce the formation of AhR/AhR nuclear translocator heterodimers and transactivate cytochrome P450 (CYP) expression. B[a]P is metabolically transactivated to reactive diolepoxides by CYP1A1 and CYP1B1 (Hecht, 2003; Nebert et al., 2004) . These metabolites cause the formation of DNA adducts and change the expression of genes implicated in cell proliferation, inflammation, and cancer progression. The biological effects of PAHs and B[a]P on neovascularization have become a great concern. In smoking-associated chronic obstructive pulmonary diseases, B[a]P-enriched cigarette smoke extract (CSE) inhibits endothelial cell migration and angiogenesis (Hecht, 2003; Michaud et al., 2006) . B[a]P oral exposure results in a marked impairment of angiogenesis in a surgically induced hindlimb ischemia model (Michaud et al., 2003; Su et al., 2004) . Ablation of AhR resulted in enhancement of ischemia-induced angiogenesis (Ichihara et al., 2009) .
Vascular endothelium is highly sensitive toward injury caused by AhR agonists. Unlike mature vessels, which are typically quiescent and resistant to angioactive agents, neovessels and their endothelium can readily remodel and respond to such factors (Madonna and De Caterina, 2008) . The main objective of the present study was to determine whether B[a]P exposure could change the phenotypic performance of primary human umbilical vein endothelial cells (HUVECs) and impair bFGF and VEGF stimulation of neovasculogenesis. We found that B[a]P-treated HUVECs exhibited reduced bFGF and VEGF induction of integrin expression, cell migration, and neovasculogenesis in comparison to solventtreated HUVECs.
MATERIALS AND METHODS
Chemicals. PAHs, including naphthalene, fluoranthene, fluorene, B[a]P, and other chemicals were all analytical grade and, unless otherwise indicated, were purchased from Sigma (St Louis, MO).
HUVECs isolation and culture. Human umbilical cords were obtained from National Taiwan University Hospital, and HUVECs were isolated by enzymatic digestion from 20-cm-long umbilical cord vein segments filled with 0.1% collagenase as previously described (Li et al., 2004) . Confluent primary cultures within passages 3-6 were used in the experiments.
Lentivirus-mediated small hairpin RNA for AhR gene silence. The VSV-G expression vector pMDG, gag-pol expression vector pCMVD8.91, and pLKO.1 encoding the AhR small hairpin RNA (shRNA) (TRCN0000021254) were cotransfected into 293T cell by calcium phosphate precipitation. All plasmids were obtained from the National RNAi core facility (Academic Sinica, Taiwan). The virus-containing supernatants were collected after 24-48 h transfection and refined through a 0.45-lm syringe filter. The viral supernatants were added to the HUVEC culture in the presence of 10 lg/ml polybrene (hexadimethrine bromide; Sigma). Two days after infection, lentivirus-infected HUVECs were used for subsequent studies.
3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay. Cytotoxicity was evaluated by the reduction of 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) (Liao et al., 2009) . HUVECs were seeded in 48-well plates (1 3 10 4 cells/well). After 24 h, HUVECs were incubated with PAHs at the indicated doses for another 24 h. After treatment, MTT was added to each well to a final concentration of 0.04 mg/ml. After 4-h incubation, the MTT solution was removed and replaced with 200 ll dimethyl sulfoxide. Absorbance of the MTT metabolic product formazan at 570 nm was measured with an ELISA microplate reader. Readings were corrected for the background optical density by subtracting the readings from a blank treatment.
Neovasculogenesis assay. The neovasculogenesis assay was performed in Matrigel-coated (BD Biosciences Discovery Labware, MA) 48-well culture plates (Nicosia and Ottinetti, 1990) . The Matrigel (130 ll/well) was polymerized for 60 min at 37°C. B[a]P-treated HUVECs were seeded onto coated plates at a density of 2 3 10 4 cells/well in M199 containing 5% fetal bovine serum (FBS) and bFGF (50 ng/ml) or VEGF (20 ng/ml) at 37°C. Neovasculogenesis was optimal after 4-8 h, began to fade after 10 h, and disappeared after 16-20 h. Therefore, the images were taken at 6 h and 340 magnification with a digital output camera (Nikon, Japan) attached to an inverted phase-contrast microscope. Total capillary-like network (in mm/ mm 2 ) in each well was measured by the Image-Pro Plus V4.5 software (Media Cybernetics, Silver Spring, MD).
In vitro cell migration assay. Migration assays were performed using a Boyden chamber (Costar, NY) with an 8-lm pore polycarbonate filter (McCarthy et al., 1983) . A fibronectin coat (20 ll at 0.2 mg/ml) was applied overnight at 4°C. B[a]P-treated HUVECs suspensions containing 2 3 10 4 cells/100 ll were placed in the upper chamber of a 48-well Boyden chamber. The lower chamber contained M199 medium with 5% FBS without seeded cells. The chemotactic factors bFGF and VEGF were individually applied to the lower chambers. Finally, the Boyden chamber was incubated at 37°C in a CO 2 incubator. To avoid the influence of cell proliferation, we allowed HUVECs to migrate across the filter for only 4 h. Cells on the upper side of the filter membranes were removed. Cells which had migrated were fixed in 3% paraformaldehyde and subjected to 0.05% crystal violet staining. The results are expressed as the number of migrated cells per square millimeter.
Cell-surface integrin expression. Integrin expression was assessed by fluorescence-activated cell sorting (FACS) with antibodies recognizing human avb3 (LM609; Chemicon, Temecula, CA). B[a]P-treated HUVECs suspensions (1 3 10 4 cells) were incubated with specific antibodies (1:100 dilution) for 45 min at 4°C. A fluorescein isothiocyanate-conjugated anti-mouse antibody (at 1:100 dilution) was added and incubated for another 45 min. After incubation, cells were fixed with 1% paraformaldehyde and quantitatively analyzed on a FACStar flow cytometer (Becton Dickinson) by measuring 10,000 cells per sample. The results are expressed in relative amounts compared with the control.
Western blots. Whole-cell lysate, protein concentration determination, SDS-PAGE, and immunoblot were performed as described previously (Li et al., 2005) . For immunodetection, the PVDF membrane was blocked in nonfat milk and incubated in TBST with antibodies specific to phospho-Erk, Erk, Akt, phospho-Akt (Santa Cruz, CA, integrin av and integrin b3 (Transduction Laboratory, MA, USA), and b-actin (Sigma). Enhanced chemiluminescence detection was performed according to the manufacturer's protocol (Millipore, MA, USA).
Statistical analysis. All data are expressed as the mean ± SD from at least three independent experiments (N 3). The significance of the difference between the control and each experimental test condition was analyzed by Student's t-test. Statistically significant differences among groups were determined using one-way ANOVA. A value of p < 0.05 was taken as statistically significant.
RESULTS

The Cytotoxic Effects of PAHs on Endothelial Cells
Cytotoxic studies of PAHs, including naphthalene, fluoranthene, anthracene, chrysene, pyrene, and B[a]P, were evaluated by MTT assay. When HUVECs were incubated with various PAHs (0.1-300lM) for 24 h, their mitochondrial activity began to decrease at 20lM. These PAHs had no cytotoxic effects on HUVECs at concentrations below 10lM. At higher concentrations, anthracene and chrysene caused mild cytotoxicity (Fig. 1) . Our data indicated that < 10lM PAHs did not exert toxic effects on HUVECs, and so these concentrations were used for the following experiments.
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Effects of PAHs on Neovasculogenesis in Endothelial Cells
The neovasculogenesis assay was performed on Matrigelcoated 48-well plates. In solvent-treated HUVECs, the formation of endothelial capillary-like network was optimal after 4-8 h, and bFGF was used as the positive control. In accordance with the quantitative data, 50 ng/ml bFGF significantly enhanced the endothelial capillary-like tube formation in comparison to the control. In PAH-treated groups, HUVEC were incubated with PAHs for 24 h, and neovasculogenesis was recorded by inverted phase-contrast microscopy and measurement using the Image-Pro Plus V4.5 software. Our data indicated that only B[a]P-treated HUVECs significantly inhibited neovasculogenesis ( Fig. 2A) . In 0.3, 3, and 10lM B[a]P-treated HUVECs, the level of neovasculogenesis decreased in a dose-dependent manner in comparison to the control (Fig. 2B ). Other PAHs, including naphthalene (20lM), phenanthrene (20lM), fluoranthene (20lM), anthracene (20lM), pyrene (20lM), and chrysene (10lM), showed no effects on neovasculogenesis in treated HUVECs ( Fig. 2A) .
Angiogenic Factor-Induced Neovasculogenesis Was Reduced in B[a]P-Treated HUVECs
In solvent-treated HUVECs, bFGF (50 ng/ml) and VEGF (20 ng/ml) enhanced neovasculogenesis after 6 h incubation, and these were used as the positive controls. In the B[a]Ptreated group, HUVECs were pretreated with 0.3, 3, and 10lM B[a]P for 24 h prior to bFGF and VEGF stimulation. bFGF-and VEGF-induced neovasculogenesis was reduced by B[a]P pretreatment in a dose-dependent manner. Significantly decreased neovasculogenesis began with 3lM B[a]P pretreatment in both bFGF-and VEGF-stimulated HUVECs (Fig. 2C) .
Angiogenic Factor-Induced Cell Migration Was Inhibited in B[a]P-Treated HUVECs
The HUVECs migration assay was performed after 4 h of incubation in a Boyden chamber. In B[a]P-treated HUVECs, the migratory cell counts were unchanged by 0.3, 3, and 10lM test doses, when compared with solvent-treated HUVECs (Fig. 3A) . However, under bFGF or VEGF stimulation, bFGF-and VEGF-induced migration were diminished in 0.3, 3, and 10lM B[a]P-treated HUVECs, and the decrease in migratory cell counts corresponded with B[a]P pretreatment in a dose-dependent manner. A significant reduction in cell migration began at 3lM of B[a]P treatment in both bFGFand VEGF-stimulated HUVECs (Fig. 3B) . 
B[a]P Inhibited Angiogenic Factor-Induced Angiogenesis
In Vivo Angiogenesis was evaluated by an in vivo chick chorioallantoic membrane (CAM) assay. A 0.2mM B[a]P-saturated disc was layered on a CAM of 8-day-old Leghorn chicken egg embryos for 24 h and subjected to 2 lg/ml bFGF or VEGF incubation for 4 days. Both bFGF and VEGF induced angiogenesis in vivo, and the angiogenic effects were diminished by B[a]P pretreatment (Supplementary fig. 2 ).
Angiogenic Factor-Induced Integrin avb3 Expression Was Reduced in B[a]P-Treated HUVECs
Growth factor-induced cell proliferation, adhesion, and migration in cultured endothelial cells often require specific integrins (Borges et al., 2000; Brooks et al., 1994; ; Byzova et al., 2000) . Abolition of the expression or function of integrin avb3 inhibits bFGF-induced angiogenesis (Brooks et al., 1994) . To analyze integrin avb3 on the cell surface, a fluorescence-conjugated antibody against integrin avb3 was used, and the fluorescence intensity was determined by flow cytometry. The data showed that bFGF increased integrin avb3 expression on HUVECs surfaces. In B[a]P-treated HUVECs, the expression of integrin avb3 was unaffected by B[a]P itself. However, bFGF induction of integrin avb3 was diminished in B[a]P-treated HUVECs (Fig. 4A) .
Protein levels of integrin av and b3 subunits in whole-cell lysates were analyzed by Western blotting. In solvent-treated HUVECs, bFGF and VEGF stimulation increased integrin av and b3 expression in a concentration-dependent manner. In B[a]P-treated HUVECs, bFGF and VEGF induction of integrin av and b3 was abolished, and the expression of integrin a5 was unaffected ( Fig. 4B; Supplementary fig. 3 ). In solvent-treated HUVECs, bFGF and VEGF increased p42/ p44 extracellular signal-regulated kinase (ERK) (Fig. 5A ) and Akt phosphorylation (Supplementary fig. 4 ) after 1 and 24 h of incubation (data not shown). In B[a]P-treated HUVECs, ERK activation, induced by bFGF and VEGF, was diminished ( Fig. 5A) , whereas Akt activation remained unchanged (Supplementary fig. 4 ). In B[a]P-treated HUVECs, p42/p44 ERK protein levels decreased in a dose-dependent manner (Fig. 5B) .
Alpha-naphthoflavone Reversed B[a]P Inhibition of MAPK and Neovasculogenesis in HUVECs
Alpha-naphthoflavone (alpha-NF), an AhR antagonist, was applied to HUVECs prior to B[a]P. Alpha-NF pretreatment (0.5lM) prevented B[a]P induction of CYP1A1 and CYP1B1 (Supplementary fig. 5 ). bFGF-and VEGF-induced p42/p44 ERK activation (Fig. 5C ), and neovasculogenesis ( Fig. 5D ) was rescued in B[a]P-treated HUVECs pretreated with alpha-NF.
AhR Is a Crucial Factor in B[a]P Inhibition of Neovasculogenesis
Lentivirus-mediated AhR silencing was performed in HUVECs (Fig. 6A) . In AhR-silenced HUVEC, B[a]P inhibition of neovasculogenesis was rescued (Supplementary  fig. 6 ). Angiogenic factor-induced neovasculogenesis was also recovered in B[a]P-treated HUVECs with silenced AhR (Fig.  6B) , indicating the requirement for AhR in B[a]P-mediated vasculotoxicity.
DISCUSSION
Tissue repair after ischemic tissue damage requires new blood vessel formation. The endothelium, the inner lining of the vasculature, is responsible for initiating neovascularization through various angiogenic and trophic factors (Somanath et al., 2009) . Recent studies have focused on ex vivo genemodified endothelial cells to enhance proangiogenic capacity (Park et al., 2009) . However, discouraging results were generated from endothelial cells exposed to environmental pollutants, which may change phenotypic outcomes and inhibit neovascularization. In the present study, HUVECs were pretreated with solvent or B[a]P, followed by angiogenic factor stimulation. We found that bFGF-and VEGF-induced neovasculogenesis and chemotaxis migration were strongly reduced in B[a]P-treated HUVECs, compared with solventtreated HUVECs (Figs. 2 and 3) . B[a]P pretreatment also inhibited bFGF-and VEGF-induced angiogenesis in vivo (Supplementary fig. 2 ). These findings suggest that B[a]Ptreated HUVECs were desensitized to stimulation by angiogenic factors.
Studies have shown that 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (Ishimura et al., 2009; , 3-methylcholanthrene (Juan FIG. 4 . Angiogenic factor-induced integrin avb3 expression was reduced in B[a]P-treated HUVECs. (A) Integrin avb3 expression on the cell surface was determined by a fluorescence-labeled antibody as described in the ''Materials and Methods'' section. bFGF treatment increased the intensity of integrin avb3, whereas B[a]P pretreatment reduced bFGF-induced integrin avb3 expression. (B) Western blots showed that the expressions of the integrin av and b3 subunits were upregulated in bFGF-and VEGF-treated HUVECs. However, the induction of integrin subunits were decreased in B[a]P-treated HUVECs. The integrin expression intensity was analyzed by densitometry. *p < 0.05, **p < 0.01, and ***p < 0.001 indicate a statistical difference with the solvent-treated control.
# p < 0.05, (Ichihara et al., 2009) , and CSE (Takeuchi et al., 2009 ) disrupt angiogenesis by inhibiting the expression of angiogenic stimuli and by reducing the responsiveness of endothelial cells to those stimuli. The biochemical mechanism of these compounds is largely mediated by AhR. B[a]P inhibition of angiogenesis was markedly rescued in AhR-null mice (Michaud et al., 2003; Su et al., 2004) . In our study, both AhR antagonist alpha-NF and AhR shRNA ameliorated the effects of B[a]P on endothelial capillary-like tube formation, indicating the involvement of AhR in regulating angiogenesis (Fig. 5) ; however, the molecular mechanism of AhR in neovascularization remains elusive.
Vascular trauma (e.g., limb ischemia, myocardial infarction) typically triggers the release of angiogenic factors, such as VEGF, GCSF, GMCSF, and FGF, which yield paracrine support for local angiogenesis and/or improve host cell proliferation and survival, thereby creating a permissive environment for rapid revascularization (Young et al., 2007) . VEGF and bFGF may promote the adhesion and migration of endothelial cells via integrin avb3, whereas the antagonists of integrin avb3 may block angiogenesis (Brooks et al., 1994; Eliceiri, 2001; Gerwins et al., 2000; Gutheil et al., 2000; Hammes et al., 1996; Tong et al., 2006) . In our study, bFGF induction of integrin avb3 was reduced in B[a]P-treated HUVECs in comparison to solvent-treated HUVECs. In addition, angiogenic factors augmented integrin av and b3 subunit expression in solvent-treated HUVECs but not in B[a]P-treated HUVECs (Fig. 4) . VEGF and bFGF bind to their cognate receptor tyrosine kinases (RTKs). Abundant evidence from in vitro and in vivo studies has demonstrated the importance of coordination of signals from the extracellular environment that activate specific RTKs and integrins (Borges et al., 2000; Munoz-Chapuli and Quesada, 2004) . Integrin ligation also induces a wide range of intracellular signal transduction pathways, including Ras, MAPK, focal adhesion kinase (FAK), Src, and PI-3 kinase (Eliceiri and Cheresh, 2001; Eliceiri et al., 1998) . AhR agonist 3-methylcholanthrene decreased FAK cell adhesion signaling and attenuated HUVECs proliferation and angiogenesis (Juan et al., 2006) . In our study, the reduction of integrin expression in B[a]Ptreated HUVECs represents the impaired synergy between angiogenic factors and integrins. We found that bFGF-and VEGF-activated MAPK phosphorylation was impaired in B[a]P-treated HUVECs (Fig. 5) , whereas PI-3 kinase/Akt signaling remained unaffected (Supplementary fig. 4 ). MAPK inhibitors (PD98059 and U-0126), but not PI-3 kinase inhibitor (LY294002), inhibit the induction of integrin av and b3 subunit expression by urokinase-type plasminogen activator receptor and glial cell-derived neurotrophic factor (GDNF) (Gellert et al., 2003; Su et al., 2009) and inhibits migration (Lee et al., 2007) and neovasculogenesis (Chung et al., 2008; Han et al., 2004; Hayashi et al., 2007; Huang et al., 2008; Mary et al., 1998) . Additionally, the attenuation of bFGF-and VEGF-induced MAPK activation in B[a]P-treated HUVECs was rescued by alpha-NF, suggesting that AhR may be associated with reduced endothelial migration signaling and altered expression of integrin proteins.
Endothelial-specific PI-3 kinase/Akt/eNOS/NO and VEGF receptor-coupled Ras/MAPK are two major pathways for endothelial cell proliferation (Eliceiri and Cheresh, 2001; Munoz-Chapuli and Quesada, 2004) and angiogenesis (Ding et al., 2006; Lee et al., 2006; Michaud et al., 2006; Tong et al., 2006) . In our study, the proliferation index remained unchanged between solvent-treated and B[a]P-treated HUVECs fig. 1 ). As a result, B[a]P did not prevent angiogenic factor-induced PI-3 kinase/Akt activation (Supplementary fig. 4 ). The inhibition of neovasculogenesis by B[a]P is therefore not simply a consequence of PI3-kinase/Akt. Neither the PI-3 kinase inhibitor nor dominant-negative mutants inhibited integrin expression or angiogenesis (Chung et al., 2008; Han et al., 2004) .
In conclusion, we found that B[a]P inhibited angiogenic factor-induced integrin expression, neovasculogenesis, and cell migration in B[a]P-treated HUVECs. The mechanism involves decreased expression of surface integrins and blockade of the MAPK pathway. B[a]P also inhibited angiogenesis in a chorioallantoic membrane assay. The results of our study suggest that AhR agonists are potent angiogenic inhibitors that may reduce the formation of neovessels and tissue regeneration. Future research will seek to identify the epigenetic changes in B[a]P-treated HUVECs, in particular the angiogenic signaling pathways disrupted by AhR agonists, and will improve our ability to assess their risk to human health.
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